


Claims


1. A compound of formula (I)



or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.


2. A compound of formula (I) according to claim 1, as the free base in the form of its Form 2 crystalline polymorph having an XRPD pattern substantially as shown in Figure 5.
3. A compound of formula (I) according to claim 1, as the free base in the form of its Form 3 crystalline polymorph having an XRPD pattern substantially as shown in Figure 12.
4. A pharmaceutical composition comprising a compound according any one of claims 1 to 3, in combination with one or more pharmaceutically acceptable diluents or carriers.
5. A pharmaceutical composition according to claim 4 further comprising a second or further active ingredient e.g. selected from corticosteroids, beta agonists, xanthines, muscarinic antagonists and p38 MAP kinase inhibitors.
6. A combination product comprising:
- (A) a compound of formula (I) according to any one of claims 1 to 3; and
 - (B) a further active ingredient e.g. selected from corticosteroids, beta agonists, xanthines, muscarinic antagonists, phosphodiesterase inhibitors and p38 MAP kinase inhibitors.
- wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable diluent or carrier.
7. A pharmaceutical composition according to claim 4 or a combination product according to claim 6 wherein the pharmaceutically acceptable diluent or carrier is lactose.
8. A compound of formula (I) according to any one of claims 1 to 3 for use as a medicament.

9. A compound of formula (I) according to any one of claims 1 to 3 for use as a medicament to be administered in combination with one or more further active ingredients e.g. selected from corticosteroids, beta agonists, xanthines, muscarinic antagonists and p38 MAP kinase inhibitors.
10. A compound of formula (I) according to any one of claims 1 to 3 or a pharmaceutical composition according to any one of claims 4, 5 or 7 or a combination product according to claim 6 for use in the treatment or prevention of a condition selected from:
COPD (including chronic bronchitis and emphysema), asthma, paediatric asthma, cystic fibrosis, sarcoidosis, idiopathic pulmonary fibrosis, allergic rhinitis, rhinitis, sinusitis, and viral induced exacerbations of any one of the same, respiratory virus infection (including the complications thereof), allergic conjunctivitis, conjunctivitis, allergic dermatitis, contact dermatitis, psoriasis, ulcerative colitis, inflamed joints secondary to rheumatoid arthritis or osteoarthritis, rheumatoid arthritis, pancreatitis, cachexia, inhibition of the growth and metastasis of tumours including non-small cell lung carcinoma, breast carcinoma, gastric carcinoma, colorectal carcinomas and malignant melanoma.
11. A compound of formula (II):




wherein LG₁ represents halo or a protected derivative thereof wherein the protecting group is a silyl group.

12. A process for preparing a compound of formula (I) according to any one of claims 1 to 3 comprising
reacting a compound of formula (II)




or a protected derivative thereof,
wherein LG₁ represents halo, with a fragment:



under conditions appropriate to provide compound of formula (I) or a protected derivative thereof wherein the protecting group is a silyl group and, if necessary, deprotecting the protected compound to yield a compound of formula (I).

13. A compound of formula (Ia)



or a pharmaceutically acceptable salt thereof, including all stereoisomers, tautomers and isotopic derivatives thereof.

14. A compound of formula (I) according to claim 1 as the free base in the form of its Form 2 crystalline polymorph having an XRPD pattern containing three, four, five six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or all twenty one peaks selected from 8.2, 9.0, 9.2, 9.7, 12.2, 14.1, 14.3, 15.0, 16.4, 18.0, 18.5, 19.0, 19.6, 21.8, 22.3, 22.5, 24.3, 24.5, 24.8, 25.1 and 25.8 (± 0.2 degrees, 2-theta values).
15. A compound of formula (I) according to claim 14 having an XRPD pattern containing one, two, three or four peaks selected from 9.7, 12.2, 14.1 and 14.3 (± 0.2 degrees, 2-theta values).